July 14, 2016Open Access
View Full PaperNovel biomarkers predicting cardiac function after acute myocardial infarction
Key Result
While traditional biomarkers are closely related to left ventricular dysfunction after AMI, the incremental value of novel biomarkers remains controversial.
Structured PICO
Do novel biomarkers provide incremental value in predicting cardiac dysfunction and clinical outcomes in patients with acute myocardial infarction?
P
Population
Patients with acute myocardial infarction (AMI)
E
Exposure
Measurement of novel biomarkers (copeptin, galectin-3, corin, fetuin-A, adiponectin, microRNA) and traditional biomarkers (cardiac troponins, natriuretic peptides)
O
Outcome
Cardiac dysfunction and clinical outcomesurrogate
While traditional biomarkers like troponins and natriuretic peptides reliably predict LV dysfunction after AMI, the clinical utility of novel biomarkers requires further validation.
Abstract
BACKGROUND: Measurement of biomarkers provides a cost-effective and widely available method to estimate cardiac dysfunction and clinical outcome of patients with acute myocardial infarction (AMI). SOURCES OF DATA: PubMed entries with terms 'myocardial infarction' and the respective biomarker. AREAS OF AGREEMENT: Cardiac troponins and natriuretic peptides are closely related to left ventricular dysfunction and the occurrence of adverse clinical events following AMI. AREAS OF CONTENTION: The incremental value of novel biomarkers is controversial. FUTURE DIRECTIONS: The combination of traditional and novel biomarkers might further improve risk stratification of patients with AMI. SEARCH STRATEGY: We searched all entries on the PubMed database with the MeSH terms 'myocardial infarction' and 'cardiac troponins', 'natriuretic peptides', 'copeptin', galectin-3', 'corin', 'fetuin-A', 'adiponectin' and 'microRNA'.